PREMIUM: PeRioperative Encorafinib+binimetinib in BRAFV600 MUtant clinically detected AJCC stage III(B/C/D) or oligometastatic stage IV Melanoma (PREMIUM)

Research summary

The PREMIUM trial is multi-centre, open label, two-arm, randomised phase II feasibility trial looking at the role of pre-operative encorafinib plus binimetinib (EncoBini) compared with the standard post-operative therapy, in patients with potentially resectable melanoma. Eligible patients will be randomised to receive either 8 weeks of pre-operative EncoBini, followed by surgery, then up to 44 weeks of EncoBini (EncoBini Arm); or to receive up to 52 weeks of the standard post-surgery treatment offered at their participating site (Standard Arm). The trial will look at whether EncoBini given before surgery, as part of a randomised trial, is accepted by these patients and their doctors; and whether there is a significant complete pathological response when pre-operative EncoBini is received. The research is funded by Pierre Fabre Ltd.

Principal Investigator

Dr Miranda Payne

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

278086